Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3) - Concepedia

Concepedia

Publication | Open Access

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

DOI Full Paper Access

27

Citations

37

References

2023

Year

Peter C. Taylor, Michael E. Weinblatt, Iain B. McInnes, Tatsuya Atsumi, Vibeke Strand, Tsutomu Takeuchi, Marguerite Bracher, David P. Brooks, John R. Davies, Christopher T. Goode,

Annals of the Rheumatic Diseases

References

	Year	Citations

Page 1